Full Title
NVL-655-01, A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)Purpose
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
Researchers think that NVL-655 may be an effective therapy for people with advanced or metastatic solid tumors with an ALK fusion because NVL-655 may continue to work after cancer cells develop resistance to other TKI treatments. NVL-655 is a tablet that is taken orally (by mouth).
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Drilon at 646-608-3758.